CCL

Összesen 4 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM020653
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients / Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G.
Dátum:2006
Megjegyzések:Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Objectives were to determine endothelial dysfunction with a non-invasive method in lupus patients and to analyse correlation with risk factors and atherosclerotic complications. Sixty-one SLE patients and 26 healthy age- and sex-matched control subjects were entered into the study. The diameters of brachial artery at rest, during reactive hyperaemia, and after glyceril trinitrate administration, as well as the intima-media thickness of the common carotid artery were measured using high-resolution B-mode ultrasonography. Demographic characteristics, lipid profile, paraoxonase activity, concentration of anti-phospholipid antibodies and anti-oxLDL were assessed together with atherosclerotic complications. The endothelium dependent vasodilation (FMD) was significantly impaired in SLE patients as compared to controls. The absolute difference of vessel diameter (Deltad) was 0.25+/-0.15 mm vs. 0.38+/-0.16 mm (p=0.001), and Deltad as in percent of the rest diameter was 7.31+/-5.2% vs. 9.86+/-3.87% (p=0.013) in lupus patients and controls, respectively. Nitrate mediated dilation (NMD) did not differ. FMD negatively correlated with age, systolic and diastolic blood pressure in SLE, but did not show significant correlation with the other examined parameters. However, FMD significantly differed between SLE patients with (5.54+/-4.36%) and without (8.81+/-5.28%) cardiovascular complications (p=0.01). The determination of flow-mediated vasodilation is a useful method to detect endothelial dysfunction in lupus patients, as reduced capacity of brachial artery may distinguish between SLE patients and healthy subjects, as well as lupus patients with and without atherosclerotic vascular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Autoimmunity. - 27 : 4 (2006), p. 211-217. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Kocsis Zsolt (1987-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

2.

001-es BibID:BIBFORM001209
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus / Tarr T., Lakos G., Bhattoa H. P., Szegedi G., Shoenfeld Y., Kiss E.
Dátum:2007
Megjegyzések:The objective of this study was to analyse whether primary antiphospholipid syndrome (PAPS) may precede and modify the characteristics of systemic lupus erythematosus (SLE). Out of the total 362 SLE patients in our service, 223 patients had antiphospholipid antibodies (aPL), of whom 110 met the criteria of antiphospholipid syndrome. In 26 cases (7.2%) PAPS appeared 5.5 years before the onset of lupus (PAPS+SLE Group). Their clinical findings were compared to lupus patients without (SLE only Group, n=26) and with secondary APS (SLE+SAPS Group, n=26). The prevalence of deep venous thrombosis, stroke/TIA, recurrent fetal loss, coronary heart disease and myocardial infarction was significantly higher in PAPS+SLE Group as compared to SLE only Group. The difference in prevalence of fetal loss (P=0.014) between PAPS+SLE and SLE+SAPS Groups was also recorded. On comparison to PAPS+SLE Group, patients without APS (SLE only Group) were younger at onset of lupus, with more frequent flares and a higher prevalence of WHO type III/IV nephritis (P=0.007), requiring higher doses of cyclophosphamide and corticosteroids. Lupus started in the form of PAPS in 7.2% of our SLE patients, who presented with more thrombotic and less inflammatory complications than in SLE patients without a prior or with a following secondary APS. Considering the long latency between the two diseases, PAPS may be a forerunner of lupus, but it may also coexist with SLE as an independent autoimmune disorder
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
association
PAPS
SLE
Association
phospholipid antibody
adolescent
adult
antiphospholipid syndrome
article
deep vein thrombosis
female
fetus wastage
heart infarction
human
ischemic heart disease
major clinical study
male
nephritis
priority journal
recurrent disease
school child
stroke
systemic lupus erythematosus
transient ischemic attack
Adolescent
Adult
Antiphospholipid Syndrome
Child
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Megjelenés:Lupus 16 : 5 (2007), p. 324-328. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

3.

001-es BibID:BIBFORM001208
035-os BibID:PMID:17283584
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients / T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, Gy. Szegedi, E. Kiss
Dátum:2007
Megjegyzések:The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL- group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL- patients who met the Sapporo criteria. LAC was more common in the APS than the aPL- group (32.1% versus 9.9%, P < 0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL- group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
antiphospholipid syndrome
primary prophylaxis
thrombosis
Primary prophylaxis
acetylsalicylic acid
beta2 glycoprotein 1 antibody
cardiolipin antibody
clopidogrel
coumarin
fibrinolytic agent
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
controlled study
disease duration
female
follow up
heart infarction
human
major clinical study
male
prevalence
priority journal
prophylaxis
risk assessment
risk factor
stroke
systemic lupus erythematosus
thrombocytopenia
thrombosis
Adult
Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Autoantigens
beta 2-Glycoprotein I
Cerebrovascular Accident
Female
Fibrinolytic Agents
Follow-Up Studies
Humans
Lupus Coagulation Inhibitor
Lupus Erythematosus, Systemic
Male
Middle Aged
Platelet Aggregation Inhibitors
Risk Factors
Thrombophilia
Thrombosis
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lupus 16 : 1 (2007), p. 39-45. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Szerző által megadott URL
Borító:

4.

001-es BibID:BIBFORM001205
035-os BibID:PMID:17916982
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:2007
Megjegyzések:Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
thrombotic manifestation
APS
Follow-up
LAC
Primary prophylaxis
acetylsalicylic acid
antithrombocytic agent
beta2 glycoprotein 1 antibody
cardiolipin antibody
coumarin
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
cerebrovascular accident
cohort analysis
controlled study
data base
deep vein thrombosis
disease association
disease course
drug efficacy
female
follow uphigh risk population
history of medicine
human
international normalized ratio
lung embolism
major clinical study
male
medical record
prevalence
prophylaxis
prospective study
stroke
systemic lupus erythematosus
thrombosis
transient ischemic attack
Adult
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Aspirin
Cohort Studies
Female
Follow-Up Studies
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Thrombosis
Time Factors
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:
Rekordok letöltése1